Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.

Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O.

Neurology. 2018 Aug 28;91(9):e867-e877. doi: 10.1212/WNL.0000000000006082. Epub 2018 Jul 27.

2.

Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.

Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O.

Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20. doi: 10.1002/acn3.266. eCollection 2016 Jan.

3.

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.

Zhang H, Ng KP, Therriault J, Kang MS, Pascoal TA, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.

Transl Neurodegener. 2018 Sep 10;7:23. doi: 10.1186/s40035-018-0127-7. eCollection 2018.

4.

CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.

Gispert JD, Monté GC, Falcon C, Tucholka A, Rojas S, Sánchez-Valle R, Antonell A, Lladó A, Rami L, Molinuevo JL.

Neurobiol Aging. 2016 Feb;38:47-55. doi: 10.1016/j.neurobiolaging.2015.10.022. Epub 2015 Nov 2.

PMID:
26827642
5.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.

6.

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.

Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P.

Alzheimers Res Ther. 2015 Dec 24;7:74. doi: 10.1186/s13195-015-0161-y.

7.

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.

Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025. Erratum in: Biol Psychiatry. 2011 Feb 15;69(4):389.

8.

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.

Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM.

PLoS One. 2015 Aug 13;10(8):e0135458. doi: 10.1371/journal.pone.0135458. eCollection 2015.

9.

Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.

Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM.

Alzheimers Res Ther. 2015 Sep 17;7(1):59. doi: 10.1186/s13195-015-0142-1.

10.

Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A.

J Alzheimers Dis. 2014;42(1):157-67. doi: 10.3233/JAD-140240.

PMID:
24820015
11.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
12.

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.

Frölich L, Peters O, Lewczuk P, Gruber O, Teipel SJ, Gertz HJ, Jahn H, Jessen F, Kurz A, Luckhaus C, Hüll M, Pantel J, Reischies FM, Schröder J, Wagner M, Rienhoff O, Wolf S, Bauer C, Schuchhardt J, Heuser I, Rüther E, Henn F, Maier W, Wiltfang J, Kornhuber J.

Alzheimers Res Ther. 2017 Oct 10;9(1):84. doi: 10.1186/s13195-017-0301-7.

13.

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.

Palmqvist S, Zetterberg H, Mattsson N, Johansson P; Alzheimer's Disease Neuroimaging Initiative, Minthon L, Blennow K, Olsson M, Hansson O; Swedish BioFINDER Study Group.

Neurology. 2015 Oct 6;85(14):1240-9. doi: 10.1212/WNL.0000000000001991. Epub 2015 Sep 9.

14.

Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.

Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB.

J Alzheimers Dis. 2016;50(3):873-86. doi: 10.3233/JAD-150897.

15.

Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.

Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2013 Oct 11;5:55. doi: 10.3389/fnagi.2013.00055. eCollection 2013.

16.

Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.

Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O.

PLoS One. 2012;7(6):e38639. doi: 10.1371/journal.pone.0038639. Epub 2012 Jun 22.

17.

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.

18.

Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.

Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H.

Expert Rev Proteomics. 2017 Apr;14(4):285-299. doi: 10.1080/14789450.2017.1304217. Epub 2017 Mar 20. Review.

PMID:
28281838
19.

Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.

Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R, Molinuevo JL.

J Alzheimers Dis. 2014;42(3):901-8. doi: 10.3233/JAD-140624.

PMID:
25024322
20.

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.

Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Nov;72(11):1275-80. doi: 10.1001/jamaneurol.2015.1867.

Supplemental Content

Support Center